AbbVie Inc. (ABBV)

Key Points The SH and PSQ ETFs provide simple inverse exposure to major U.S. market indexes. For bearish-leaning risk takers, the SPXS ETF offers powerful leverage when the S&P 500 declines. Are y...

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal...

Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten...

Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal...

Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.

Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.

AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This prot...

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.

Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t...